[go: up one dir, main page]

WO2006056607A8 - Substituierte pteridine zur behandlung von entzündlichen erkrankungen - Google Patents

Substituierte pteridine zur behandlung von entzündlichen erkrankungen

Info

Publication number
WO2006056607A8
WO2006056607A8 PCT/EP2005/056247 EP2005056247W WO2006056607A8 WO 2006056607 A8 WO2006056607 A8 WO 2006056607A8 EP 2005056247 W EP2005056247 W EP 2005056247W WO 2006056607 A8 WO2006056607 A8 WO 2006056607A8
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory diseases
treating inflammatory
diseases
substituted pteridines
pteridines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/056247
Other languages
English (en)
French (fr)
Other versions
WO2006056607A1 (de
Inventor
Domnic Martyres
Juergen Mack
Horst Dollinger
Peter Nickolaus
Birgit Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2007006357A priority Critical patent/MX2007006357A/es
Priority to CA002589209A priority patent/CA2589209A1/en
Priority to AU2005308785A priority patent/AU2005308785A1/en
Priority to BRPI0516626-8A priority patent/BRPI0516626A/pt
Priority to JP2007541996A priority patent/JP2008521775A/ja
Priority to EP05813409A priority patent/EP1828189A1/de
Priority to NZ556152A priority patent/NZ556152A/en
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of WO2006056607A1 publication Critical patent/WO2006056607A1/de
Publication of WO2006056607A8 publication Critical patent/WO2006056607A8/de
Priority to IL183447A priority patent/IL183447A0/en
Anticipated expiration legal-status Critical
Priority to IL209879A priority patent/IL209879A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft neue Pteridine, die geeignet sind zur Behandlung von Atemwegs- oder gastrointestinalen Beschwerden oder Erkrankungen, entzündlichen Erkrankungen der Gelenke, der Haut oder der Augen, Erkrankungen des periphären oder zentralen Nervensystems oder Krebserkrankungen, sowie pharmazeutische Zusammensetzungen, die diese Verbindungen beinhalten.
PCT/EP2005/056247 2004-11-29 2005-11-25 Substituierte pteridine zur behandlung von entzündlichen erkrankungen Ceased WO2006056607A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002589209A CA2589209A1 (en) 2004-11-29 2005-11-25 Substituted pteridines for treating inflammatory diseases
AU2005308785A AU2005308785A1 (en) 2004-11-29 2005-11-25 Substituted pteridines for treating inflammatory diseases
BRPI0516626-8A BRPI0516626A (pt) 2004-11-29 2005-11-25 pteridinas substituìdas e uso das mesmas
JP2007541996A JP2008521775A (ja) 2004-11-29 2005-11-25 炎症性疾患治療用の置換プテリジン
EP05813409A EP1828189A1 (de) 2004-11-29 2005-11-25 Substituierte pteridine zur behandlung von entz]ndlichen erkrankungen
MX2007006357A MX2007006357A (es) 2004-11-29 2005-11-25 Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.
NZ556152A NZ556152A (en) 2004-11-29 2005-11-25 Substituted pteridines for treating inflammatory diseases
IL183447A IL183447A0 (en) 2004-11-29 2007-05-28 Substituted pteridines for treating inflammatory diseases
IL209879A IL209879A0 (en) 2004-11-29 2010-12-09 Substituted pteridines ,pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating inflammatory diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004057618A DE102004057618A1 (de) 2004-11-29 2004-11-29 Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057618.1 2004-11-29

Publications (2)

Publication Number Publication Date
WO2006056607A1 WO2006056607A1 (de) 2006-06-01
WO2006056607A8 true WO2006056607A8 (de) 2007-01-18

Family

ID=35789067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/056247 Ceased WO2006056607A1 (de) 2004-11-29 2005-11-25 Substituierte pteridine zur behandlung von entzündlichen erkrankungen

Country Status (17)

Country Link
US (1) US7550472B2 (de)
EP (1) EP1828189A1 (de)
JP (1) JP2008521775A (de)
KR (1) KR20070090975A (de)
CN (1) CN101065382A (de)
AR (1) AR054992A1 (de)
AU (1) AU2005308785A1 (de)
BR (1) BRPI0516626A (de)
CA (1) CA2589209A1 (de)
DE (1) DE102004057618A1 (de)
IL (2) IL183447A0 (de)
MX (1) MX2007006357A (de)
NZ (1) NZ556152A (de)
RU (1) RU2007124328A (de)
TW (1) TW200633711A (de)
WO (1) WO2006056607A1 (de)
ZA (1) ZA200703125B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004057595A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057645A1 (de) * 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
DE102004057594A1 (de) * 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
EP2032585B1 (de) * 2006-05-24 2014-07-23 Boehringer Ingelheim International GmbH Substituierte pteridine als therapeutika
BRPI0712381A2 (pt) * 2006-06-06 2012-07-10 Avigen Inc compostos de pirazolo[1,5-a]piridina substituìda e seus métodos de uso
EP3102939A4 (de) * 2014-02-05 2018-02-28 Dana-Farber Cancer Institute, Inc. Mittel zur modulierung der rgmb-neogenin-bmp-signalisierung und verfahren zur verwendung davon
RS67241B1 (sr) 2017-10-23 2025-10-31 Boehringer Ingelheim Int Nova kombinacija aktivnih agensa za lečenje progresivnih fibroznih intersticijalnih bolesti pluća (pf-ild)
CN113876761B (zh) * 2020-07-01 2022-12-20 广州华真医药科技有限公司 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用
ES3041145T3 (en) 2021-12-09 2025-11-07 Boehringer Ingelheim Int New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP2024541514A (ja) 2021-12-09 2024-11-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 進行性線維化を伴う間質性肺疾患を処置するための、新たな治療的組合せ
CN119947728A (zh) 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
DE3323932A1 (de) 1983-07-02 1985-01-10 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel
US4560685A (en) 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DE3540952C2 (de) 1985-11-19 1997-08-14 Thomae Gmbh Dr K 2-Piperazino-pteridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69920757T2 (de) 1998-12-28 2005-12-15 4 AZA Bioscience N.V. Immunosuppressive wirkungen von pteridinderivaten
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
DE10202468A1 (de) 2002-01-23 2004-09-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung
DE102004057595A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057645A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057594A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen

Also Published As

Publication number Publication date
IL183447A0 (en) 2007-09-20
EP1828189A1 (de) 2007-09-05
CA2589209A1 (en) 2006-06-01
AR054992A1 (es) 2007-08-01
IL209879A0 (en) 2011-02-28
JP2008521775A (ja) 2008-06-26
KR20070090975A (ko) 2007-09-06
US20060116372A1 (en) 2006-06-01
ZA200703125B (en) 2008-09-25
BRPI0516626A (pt) 2008-09-16
MX2007006357A (es) 2007-06-20
AU2005308785A1 (en) 2006-06-01
TW200633711A (en) 2006-10-01
NZ556152A (en) 2009-06-26
DE102004057618A1 (de) 2006-06-01
RU2007124328A (ru) 2009-02-20
US7550472B2 (en) 2009-06-23
WO2006056607A1 (de) 2006-06-01
CN101065382A (zh) 2007-10-31

Similar Documents

Publication Publication Date Title
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2007135026A3 (de) Substituierte pteridine als therapeutika
WO2006058867A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2005046603A3 (en) Pyridine compounds
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
WO2006058869A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
ATE549338T1 (de) Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
WO2009050242A3 (de) Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
TW200612892A (en) Novel compounds
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
EP2305640A3 (de) Substituierte Diphenyl-Ether, -Amine, -Sulfide und -Methane zur Behandlung von Beschwerden der Atemwege
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
WO2007052023A3 (en) Novel compounds
WO2008153937A3 (en) Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2007070433A3 (en) 2-arylthiazole derivatives as cxcr3 receptor modulators
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007064553A3 (en) Thiazole derivatives as cxcr3 receptor modulators
WO2006056607A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
WO2007068750A3 (en) Immunoglobulins directed against nogo
WO2006035282A3 (en) Muscarinic receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005813409

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2589209

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 183447

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/006357

Country of ref document: MX

Ref document number: 12007501127

Country of ref document: PH

Ref document number: 200580040828.9

Country of ref document: CN

Ref document number: 2007541996

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4117/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005308785

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 556152

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020077014857

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007124328

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2005308785

Country of ref document: AU

Date of ref document: 20051125

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005308785

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005813409

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0516626

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 209879

Country of ref document: IL